ArticleFrontiers in psychiatry2026
The developmental dopamine trajectory hypothesis of ADHD across the lifespan.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is increasingly recognized as a lifespan neurodevelopmental disorder, yet the mechanisms underlying its changing clinical presentation across development remain poorly understood. Although childhood ADHD is typically characterized by hyperactivity, impulsivity, and inattention, symptom expression frequently evolves during adolescence and adulthood toward greater reward dysregulation, executive dysfunction, motivational impairment, internal restlessness, and changing manifestations of emotional dysregulation. Existing neurobiological models have substantially advanced understanding of ADHD pathophysiology but provide limited explanation for how symptom continuity can coexist with developmental changes in clinical expression. Here, we propose the Developmental Dopamine Trajectory Hypothesis, which posits that DAT related dopaminergic dysregulation may interact with the sequential maturation of frontostriatal, mesolimbic, and mesocortical circuits to contribute to developmental changes in ADHD symptom expression across the lifespan. A central proposition of the framework is that the functional consequences of DAT related dopaminergic dysregulation depend on the developmental state of the neural circuits on which it acts. Within this framework, childhood manifestations may arise primarily from interactions between dopaminergic vulnerability and developing frontostriatal networks, adolescent manifestations from increasing involvement of reward and emotion related circuitry, and adult manifestations from interactions with mature executive control and motivational systems. By integrating evidence from longitudinal clinical studies, neuroimaging, electrophysiology, pharmacology, genetics, and translational DAT models, the proposed framework provides a mechanistic model for how developmental changes in neural circuit state may contribute to changing symptom expression despite continuity of underlying neurobiological vulnerability. The hypothesis generates testable predictions regarding longitudinal symptom trajectories, developmental biomarker changes, potential developmental differences in treatment responsiveness, and adolescence as a proposed critical neurodevelopmental transition period. Reconceptualizing ADHD through a developmental dopaminergic framework places developmental timing and neural circuit maturation at the center of the relationship between dopaminergic vulnerability and clinical phenotype, providing a basis for future longitudinal, mechanistic, and developmentally informed research across the lifespan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.